Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.37 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.37 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31749574 | 0.91 | PTPN11 (0.34) | PDE4APDE4BPDE4CPDE4DRXFP1 | |
| SCHEMBL5091457 | 0.89 | MAPK1 (0.38) | MAPK1MAPK3TAOK1PRKD2ALDH1A1 | |
| SCHEMBL31749267 | 0.82 | MAPK1 (0.45) | MAPK1MAPK3CCR6CDK9 | |
| SCHEMBL31167643 | 0.81 | MAPK1 (0.37) | MAPK1MAPK3TAOK1PRKD2PDE4A | |
| SCHEMBL31749244 | 0.78 | ABL1 (0.41) | PDE4APDE4BPDE4CPDE4DHDAC3 | |
| SCHEMBL22599761 | 0.76 | MAPK1 (0.40) | MAPK1MAPK3TAOK1PRKD2CDK9 | |
| SCHEMBL5091646 | 0.75 | POLB (0.32) | ALDH1A1POLB | |
| SCHEMBL31749216 | 0.75 | CCR6 (0.44) | CCR6KCNQ1LMNA | |
| SCHEMBL1718745 | 0.74 | JAK2 (0.41) | PDE4APDE4BPDE4CPDE4DHDAC3 | |
| SCHEMBL28623972 | 0.73 | PDE4A (0.37) | PDE4APDE4BPDE4CPDE4DL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183276-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183276-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183276-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-06-15 | — | — | US | disclosed |
| US-RE49500-E1 | Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-04-25 | — | — | US | disclosed |
| EP-3943489-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | Vertex Pharmaceuticals Incorporated (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943489-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | Vertex Pharmaceuticals Incorporated (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3608315-B1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | VERTEX PHARMA (US) | 2021-08-11 | — | — | EP | disclosed |
| US-RE48266-E1 | Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-10-20 | — | — | US | disclosed |
| US-RE48266-E1 | Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-10-20 | — | — | US | disclosed |
| EP-3608315-A1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | Vertex Pharmaceuticals Incorporated (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20160221987-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. | 2016-08-04 | — | — | US | disclosed |
| EP-2799434-A1 | Pyrrole compounds as inhibitors of ERK protein kinases and pharmaceutical compositions containing these compounds | Vertex Pharmaceuticals Incorporated (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2799434-A1 | Pyrrole compounds as inhibitors of ERK protein kinases and pharmaceutical compositions containing these compounds | Vertex Pharmaceuticals Incorporated (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-1753738-B1 | Pyrrole compounds as inhibitors of ERK protein kinases and pharmaceutical compositions containing these compounds | VERTEX PHARMA (US) | 2014-07-09 | — | — | EP | disclosed |
| US-7354939-B2 | 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester; mitogen-activated protein kinase inhibitor; antiproliferative, anticarcinogenic agent; study of intracellular signal transduction pathways; evaluation of new kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354939-B2 | 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester; mitogen-activated protein kinase inhibitor; antiproliferative, anticarcinogenic agent; study of intracellular signal transduction pathways; evaluation of new kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-08 | — | — | US | disclosed |
| US-7354939-B2 | 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester; mitogen-activated protein kinase inhibitor; antiproliferative, anticarcinogenic agent; study of intracellular signal transduction pathways; evaluation of new kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1753738-A1 | PYRROLE COMPOUNDS AS INIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | Vertex Pharmaceuticals Incorporated (US) | 2007-02-21 | — | — | EP | disclosed |
| US-20060106069-A1 | 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester; mitogen-activated protein kinase inhibitor; antiproliferative, anticarcinogenic agent; study of intracellular signal transduction pathways; evaluation of new kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-05-18 | — | — | US | disclosed |
| WO-2005113541-A1 | PYRROLE COMPOUNDS AS INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183276-A1 | PYRROLE INHIBITORS OF ERK PROTEIN KINASE, SYNTHESIS THEREOF AND INTERMEDIATES THERETO | MAPK1, MAP3K1, MAP3K20 | MAPK1 1/4885MAPK3 20/4885TAOK1 136/4885 |
| US-20160221987-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | MAPK1 3078/4885MAPK3 4411/4885TAOK1 1886/4885 |
| US-20060106069-A1 | 4-(5-Chloro-2-isopropylaminopyridin-4-yl)-1-(toluene-4-sulfonyl)-1H-pyrrole-2-carboxylic acid methyl ester; mitogen-activated protein kinase inhibitor; antiproliferative, anticarcinogenic agent; study of intracellular signal transduction pathways; evaluation of new kinase inhibitors | MAP3K1, MAP4K2, MAP3K4 | MAPK1 27/4885MAPK3 31/4885TAOK1 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.